Oct 16
2023
Phanes Therapeutics, Inc. announces clinical trial collaboration and supply agreement with Merck to evaluate PT886 in combination with KEYTRUDA® (pembrolizumab)
PT886 is Phanes' first-in-class bispecific antibody targeting claudin 18.2 and CD47; KEYTRUDA® (pembrolizumab) is Merck's anti-PD-1 The clinical trial collaboration will...
Read More
Sep 14
2023
Phanes Therapeutics announces the appointment of internationally renowned oncologist Prof. Shun Lu to its Clinical Advisory Board
SAN DIEGO, Sept. 14, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Sep 7
2023
Phanes Therapeutics announces first patient dosed in phase 1 study of PT217 for small cell lung cancer and other neuroendocrine cancers expressing DLL3
PT217 is a first-in-class bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47) and is Phanes' third program...
Read More
Sep 5
2023
Phanes Therapeutics announces the establishment of oncology Clinical Advisory Board
Distinguished, world renowned experts appointed to strengthen the development of Phanes' three clinical programs in oncology SAN DIEGO, Sept. 5, 2023 /PRNewswire/...
Read More
May 30
2023
Phanes Therapeutics announces the appointment of Rita Laeufle, MD, PhD, as Chief Medical Officer
SAN DIEGO, May 30, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
May 3
2023
GEN article: bispecific antibodies expose tumors to new lines of attack
Original link: Bispecific Antibodies Expose Tumors to New Lines of Attack (genengnews.com) By Amanda Heidt Ever since the first bispecific...
Read More
Mar 20
2023
Phanes Therapeutics announces first patient dosed in phase 1 study of PT886 for advanced gastric, gastroesophageal junction and pancreatic adenocarcinomas
SAN DIEGO, March 20, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More
Mar 6
2023
Phanes Therapeutics entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas company
SAN DIEGO, March 6, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development...
Read More
Jan 17
2023
Phanes Therapeutics’ anti-claudin 18.2 antibody patent granted in the US
SAN DIEGO, Jan. 17, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Dec 8
2022
Phanes Therapeutics announces clinical supply agreement with BeiGene to evaluate PT199 in combination with tislelizumab
SAN DIEGO, Dec. 8, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
